EGT 022

Drug Profile

EGT 022

Alternative Names: EG 22; EG-Decorin; EG-Mirotin; EGT022; HU-005

Latest Information Update: 04 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EyeGene
  • Developer EyeGene; Huons
  • Class Membrane proteins; Recombinant proteins
  • Mechanism of Action Angiogenesis inducing agents; Platelet derived growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Pressure ulcer
  • Phase I Diabetic retinopathy
  • Preclinical Diabetic foot ulcer; Retinopathy of prematurity

Most Recent Events

  • 04 May 2016 EGT 022 is still in phase I/II trials for Pressure ulcer in South Korea (Topical)
  • 04 Feb 2014 EGT 022 is available for licensing as of 01 Jan 2013.
  • 01 Jan 2013 Phase-I trials in Diabetic retinopathy in European Union (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top